What is dexamethasone? A drug that boosts Covid-19 survival chance

Low-cost, widely-used steroid dexamethasone is first to show life-saving promise

dexamethasone, covid vaccine, coronavirus
Britain says the drug has been approved for use in the state-run health service, and export restrictions have been introduced
Reuters London
2 min read Last Updated : Jun 17 2020 | 2:00 AM IST
A cheap and widely used steroid called dexamethasone has become the first drug shown to be able to save lives among Covid-19 patients in what scientists said is a “major breakthrough” in the coronavirus pandemic.

Trial results announced on Tuesday showed dexamethasone, which is used to reduce inflammation in other diseases such as arthritis, reduced death rates by around a third among the most severely ill of Covid-19 patients admitted to hospital.

The preliminary results suggest the drug should immediately become standard care in patients with severe cases of the pandemic disease, said the researchers who led the trials. The researchers said they would work to publish the full details of the trial as soon as possible, with some scientists saying they wished to review the evidence for themselves.

 


Britain’s health ministry wasted no time in acting on the findings, saying the drug had been approved for use in the state-run health service, export restrictions had been introduced, and Britain had stockpiled 200,000 courses of the treatment.

“This is a (trial) result that shows that if patients who have Covid-19 and are on ventilators or on oxygen are given dexamethasone, it will save lives, and it will do so at a remarkably low cost,” said Martin Landray, an Oxford University professor co-leading the trial, known as the Recovery trial. 

“It’s going to be very hard for any drug really to replace this, given that for less than 50 pounds ($63), you can treat eight patients and save a life,” he said in an online briefing. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusLockdownCoronavirus Vaccine

Next Story